HIV-associated non-Hodgkin lymphoma: viral origins and therapeutic options

Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):584-9. doi: 10.1182/asheducation-2014.1.584. Epub 2014 Nov 18.

Abstract

HIV infection is associated with an increased risk of malignancy, especially B-cell lymphoid malignancies. Many of these lymphomas are further driven by concomitant infection with viruses such as Epstein-Barr virus or Human Herpesvirus 8, the latter being implicated in uncommon types of lymphomas seen in the setting of HIV-1 infection. Treatment outcomes have improved due to infusional chemotherapy, high-dose chemotherapy, and effective antiretroviral therapy. Successful functional cure of HIV-1 infection has been demonstrated with the use of allogeneic hematopoietic stem cell transplantation. This result spurred a change in the field of HIV-1 management so that, ultimately, the goals of therapy would shift from not only curing the underlying lymphoma, but also curing the HIV-1 infection. Treatment options will be discussed with an emphasis on hematopoietic cell-based therapy for the underlying HIV infection.

Publication types

  • Review

MeSH terms

  • Disease Reservoirs / virology
  • Dose-Response Relationship, Immunologic
  • HIV Infections / complications*
  • HIV Infections / therapy
  • HIV-1 / immunology
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Lymphoma, Non-Hodgkin / complications
  • Lymphoma, Non-Hodgkin / therapy*
  • Lymphoma, Non-Hodgkin / virology*